Douglass Winthrop Advisors LLC Sells 10,985 Shares of Johnson & Johnson $JNJ

Key Points

• Douglass Winthrop Advisors LLC has reduced its holdings in Johnson & Johnson by 10.0%, owning 98,424 shares worth approximately $16.32 million after selling 10,985 shares in the 1st quarter.
• Johnson & Johnson recently reported earnings of $2.77 per share, exceeding estimates, with revenue of $23.74 billion for the quarter, reflecting a year-over-year increase of 5.8%.
• The company also announced a quarterly dividend of $1.30, set to be paid on September 9th, contributing to an annualized dividend yield of 2.9%.

Douglass Winthrop Advisors LLC cut its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 98,424 shares of the company's stock after selling 10,985 shares during the period. Douglass Winthrop Advisors LLC's holdings in Johnson & Johnson were worth $16,323,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lantz Financial LLC lifted its holdings in Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares during the period. Sulzberger Capital Advisors Inc. purchased a new stake in Johnson & Johnson in the fourth quarter worth about $453,000. Joel Isaacson & Co. LLC lifted its holdings in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares during the period. State of Wyoming lifted its holdings in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after buying an additional 10,279 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. lifted its holdings in Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after buying an additional 4,816 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $0.1680 during trading hours on Friday, reaching $179.0980. The company had a trading volume of 9,523,149 shares, compared to its average volume of 8,657,504. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The firm has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 2.28 and a beta of 0.41. The firm's 50 day moving average price is $163.48 and its 200-day moving average price is $159.30.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. The firm's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. Citigroup lifted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Guggenheim reissued a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.